Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S224000, C544S242000, C544S297000, C546S268100, C546S276400, C546S277700, C548S125000, C548S136000, C548S262200, C548S300100, C548S311100, C548S364100, C548S530000, C548S537000, C514S275000, C514S336000, C514S340000, C514S424000
Reexamination Certificate
active
10776657
ABSTRACT:
Melanocortin receptor-specific pyrrolidine compounds having the structure:and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3are as described in the specification, preferably where R3is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.
REFERENCES:
patent: 4148923 (1979-04-01), Guidicelli et al.
patent: 4239763 (1980-12-01), Milavec et al.
patent: 4626549 (1986-12-01), Molly et al.
patent: 4680289 (1987-07-01), Applezweig
patent: 4937267 (1990-06-01), Holloway et al.
patent: 5120713 (1992-06-01), Mugica
patent: 5494919 (1996-02-01), Morriello et al.
patent: 5721250 (1998-02-01), Morriello et al.
patent: 5721251 (1998-02-01), Chen et al.
patent: 5804578 (1998-09-01), Chakravarty et al.
patent: 5877182 (1999-03-01), Nargund et al.
patent: 5880125 (1999-03-01), Nargund
patent: 5965565 (1999-10-01), Chen et al.
patent: 6033656 (2000-03-01), Mikami et al.
patent: 6127424 (2000-10-01), Martin et al.
patent: 6140354 (2000-10-01), Dax et al.
patent: 6162805 (2000-12-01), Hefti
patent: 6191117 (2001-02-01), Kozachuk
patent: 6207699 (2001-03-01), Rothman
patent: 6214831 (2001-04-01), Yokoo et al.
patent: 6284735 (2001-09-01), Girten et al.
patent: 6350760 (2002-02-01), Bakshi et al.
patent: 6376509 (2002-04-01), Bakshi et al.
patent: 6410548 (2002-06-01), Nargund et al.
patent: 6451783 (2002-09-01), Hadcock et al.
patent: 6458790 (2002-10-01), Palucki et al.
patent: 6472398 (2002-10-01), Palucki et al.
patent: 6515122 (2003-02-01), Lang et al.
patent: 6534503 (2003-03-01), Dines et al.
patent: 6579968 (2003-06-01), Blood et al.
patent: 2002/0004512 (2002-01-01), Bakshi et al.
patent: 2002/0072604 (2002-06-01), Carpino et al.
patent: 2002/0137664 (2002-09-01), Bakshi et al.
patent: 2002/0143141 (2002-10-01), Chen et al.
patent: 2002/0173512 (2002-11-01), Moltzen et al.
patent: 2003/0004162 (2003-01-01), Treadway
patent: 2003/0055247 (2003-03-01), Cosford et al.
patent: 2003/0055265 (2003-03-01), Binggeli et al.
patent: 2003/0069169 (2003-04-01), Macor et al.
patent: 2003/0083228 (2003-05-01), Carpino et al.
patent: 2003/0109556 (2003-06-01), Mazur et al.
patent: WO 96/38471 (1996-12-01), None
patent: WO 98/10653 (1998-03-01), None
patent: WO 99/58501 (1999-11-01), None
patent: WO 00/05373 (2000-02-01), None
patent: WO 00/35952 (2000-06-01), None
patent: WO 00/40247 (2000-07-01), None
patent: WO 01/12176 (2001-02-01), None
patent: WO 01/21634 (2001-03-01), None
patent: WO 01/21647 (2001-03-01), None
patent: WO 01/182210 (2001-03-01), None
patent: WO 01/23392 (2001-04-01), None
patent: WO 01/30343 (2001-05-01), None
patent: WO 01/55106 (2001-08-01), None
patent: WO 01/55107 (2001-08-01), None
patent: WO 01/55109 (2001-08-01), None
patent: WO 02/12178 (2002-02-01), None
patent: WO 02/18437 (2002-03-01), None
patent: WO 02/47670 (2002-06-01), None
patent: WO 02/059108 (2002-08-01), None
patent: WO 02/064091 (2002-08-01), None
patent: WO 02/067869 (2002-09-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/079203 (2002-10-01), None
patent: WO 02/079753 (2002-10-01), None
patent: WO 03/006620 (2003-01-01), None
patent: WO 03/009847 (2003-02-01), None
patent: WO 03/013509 (2003-02-01), None
patent: WO 02/085925 (2003-06-01), None
patent: WO 03/061660 (2003-07-01), None
patent: WO 02/081443 (2003-10-01), None
“Synthetic Peptides: A Users Guide,” GA Grant, editor, W.H. Freeman & Co., New York, 1992 (pp. 11-24).
Hruby, VJ, Al-Obeidi, F., and Kazmierski, W.: BioChem Journal 268:249-262, 1990.
Toniolo, C., “Conformationally Restricted Peptides Through Sort-Range Cyclizations,” International Journal Peptide Research, 35:287-300, 1990.
Hadley, M.E., et al., “Discovery and Devleopment of the Novel Melanogenic Drugs,” Integration of Pharmaceutical Discovery and Development: Case Studies, Borschart, et al. editors, Plenum Press, New York (1998).
Dorr, R.T., et al., Evaluation of Melanotan-II, A Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study, Life Sciences 58:1777-1784 (1996).
Adan, R.A.H., “Identification of Antagonists for Melanocrotin MC3, MC4, and MC5 Receptors”, European Journal Pharmacology, 269:331-337 (1994).
Merrifield, R.B., “Solid Phase Synthesis” (Nobel Lecture), Agnew Chem 24:799-810 (1985).
Rajpurohit Ramesh
Sharma Shubh D.
Shi Yi-Qun
Wu Zhijun
Palatin Technologies Inc.
Shameem Golam M. M.
Slusher Stephen A.
LandOfFree
Pyrrolidine melanocortin-specific compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine melanocortin-specific compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine melanocortin-specific compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3738342